Total Payments
$304,262
2024 Payments
$18,453
Companies
103
Transactions
1,404
Medicare Patients
8,189
Medicare Billing
$3.2M
Payment Breakdown by Category
Consulting$167,461 (55.0%)
Other$77,798 (25.6%)
Food & Beverage$29,512 (9.7%)
Travel$28,598 (9.4%)
Education$893.60 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $167,461 | 77 | 55.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $42,395 | 23 | 13.9% |
| Honoraria | $35,403 | 19 | 11.6% |
| Food and Beverage | $29,512 | 1,144 | 9.7% |
| Travel and Lodging | $28,598 | 118 | 9.4% |
| Education | $893.60 | 23 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Rigel Pharmaceuticals, Inc. | $75,158 | 110 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $37,519 | 115 | $0 (2024) |
| Dova Pharmaceuticals | $16,351 | 20 | $0 (2021) |
| Seagen Inc. | $12,667 | 22 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $10,775 | 8 | $0 (2019) |
| TESARO, Inc. | $10,632 | 14 | $0 (2019) |
| PFIZER INC. | $9,781 | 98 | $0 (2024) |
| Janssen Biotech, Inc. | $8,900 | 82 | $0 (2024) |
| GENZYME CORPORATION | $8,469 | 33 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $8,422 | 26 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18,453 | 179 | AstraZeneca Pharmaceuticals LP ($6,097) |
| 2023 | $36,057 | 189 | Seagen Inc. ($11,145) |
| 2022 | $46,888 | 187 | Rigel Pharmaceuticals, Inc. ($21,172) |
| 2021 | $27,199 | 156 | Rigel Pharmaceuticals, Inc. ($8,843) |
| 2020 | $47,980 | 201 | Regeneron Healthcare Solutions, Inc. ($6,891) |
| 2019 | $80,329 | 280 | Rigel Pharmaceuticals, Inc. ($34,895) |
| 2018 | $31,122 | 148 | AstraZeneca Pharmaceuticals LP ($9,986) |
| 2017 | $16,235 | 64 | Teva Pharmaceuticals USA, Inc. ($6,254) |
All Payment Transactions
1,404 individual payment records from CMS Open Payments — Page 1 of 57
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | Truqap (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY | Food and Beverage | In-kind items and services | $23.24 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $16.92 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $22.86 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Consulting Fee | Cash or cash equivalent | $2,622.00 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Geron Corporation | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 12/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $77.75 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $30.19 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Travel and Lodging | In-kind items and services | $12.37 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $16.26 | General |
| Category: NONE | ||||||
| 11/19/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $23.27 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $15.19 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $38.64 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/14/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $23.64 | General |
| Category: NONE | ||||||
| 11/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $19.28 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: Oncology | ||||||
| 11/07/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $13.02 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Food and Beverage | Cash or cash equivalent | $19.59 | General |
| Category: Interventional Oncology | ||||||
| 11/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Food and Beverage | In-kind items and services | $16.96 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | AstraZeneca Pharmaceuticals LP | IMJUDO (Biological) | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: Oncology | ||||||
| 10/31/2024 | AstraZeneca Pharmaceuticals LP | IMJUDO (Biological) | Food and Beverage | In-kind items and services | $28.73 | General |
| Category: Oncology | ||||||
| 10/29/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $22.54 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 10/29/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $14.39 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $21.64 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 43 | 2,171 | 128,584 | $3.6M | $788,963 |
| 2022 | 36 | 1,695 | 74,258 | $2.0M | $388,994 |
| 2021 | 44 | 2,160 | 85,635 | $3.7M | $1.0M |
| 2020 | 47 | 2,163 | 112,335 | $4.5M | $1.0M |
Total Patients
8,189
Total Services
400,812
Medicare Billing
$3.2M
Procedure Codes
170
All Medicare Procedures & Services
170 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 11 | 9,800 | $1.3M | $424,950 | 31.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 16 | 6,000 | $392,760 | $109,871 | 28.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 411 | 899 | $330,832 | $79,698 | 24.1% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 25 | 28 | $134,456 | $33,247 | 24.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 57 | 308 | $217,756 | $30,526 | 14.0% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 14 | 6,440 | $128,800 | $15,043 | 11.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 93 | 306 | $95,778 | $13,951 | 14.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 107 | 107 | $60,455 | $12,382 | 20.5% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 13 | 1,750 | $49,000 | $9,615 | 19.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 56 | 377 | $59,189 | $8,262 | 14.0% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 54 | 45,800 | $91,600 | $7,112 | 7.8% |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 2023 | 16 | 33,140 | $66,280 | $5,223 | 7.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 178 | 497 | $9,940 | $4,120 | 41.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 67 | 385 | $36,960 | $4,020 | 10.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 180 | 520 | $18,720 | $3,867 | 20.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 19 | 76 | $26,144 | $3,785 | 14.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 31 | 45 | $11,250 | $3,049 | 27.1% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 15 | 354 | $152,574 | $2,334 | 1.5% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 20 | 23 | $15,111 | $2,084 | 13.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 16 | 91 | $14,651 | $1,947 | 13.3% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 101 | 123 | $7,380 | $1,632 | 22.1% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 41 | 96 | $9,600 | $1,461 | 15.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 106 | 135 | $8,640 | $1,388 | 16.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 12 | 17 | $3,927 | $1,173 | 29.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 33 | 99 | $10,692 | $1,156 | 10.8% |
About Dr. Ashwani Agarwal, M.D
Dr. Ashwani Agarwal, M.D is a Medical Oncology healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1801837497.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ashwani Agarwal, M.D has received a total of $304,262 in payments from pharmaceutical and medical device companies, with $18,453 received in 2024. These payments were reported across 1,404 transactions from 103 companies. The most common payment nature is "Consulting Fee" ($167,461).
As a Medicare-enrolled provider, Agarwal has provided services to 8,189 Medicare beneficiaries, totaling 400,812 services with total Medicare billing of $3.2M. Data is available for 4 years (2020–2023), covering 170 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Dallas, TX
- Active Since 06/08/2006
- Last Updated 05/31/2019
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1801837497
Products in Payments
- Tavalisse (Drug) $71,764
- Doptelet (Drug) $16,422
- TAGRISSO (Drug) $11,288
- TUKYSA (Drug) $11,211
- ZEJULA (Drug) $10,952
- BRAFTOVI (Drug) $9,955
- LIBTAYO (Biological) $9,550
- IMBRUVICA (Drug) $7,722
- IMFINZI (Biological) $7,530
- Kyprolis (Biological) $6,722
- BENDEKA (Drug) $6,275
- DARZALEX (Biological) $5,306
- ADCETRIS (Biological) $4,932
- Cabometyx (Drug) $4,389
- IMFINZI (Drug) $4,159
- CALQUENCE (Drug) $3,756
- SARCLISA (Biological) $3,586
- Tecartus (Drug) $3,300
- ACCRUFER (Drug) $3,282
- Lenvima (Drug) $3,152
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Dallas
Dr. Moshe Levy, Md, MD
Medical Oncology — Payments: $5.0M
Medical Oncology $5.0M
Dr. Eric Nadler, Md, MD
Medical Oncology — Payments: $1.8M
Medical Oncology $1.8M
Dr. Joyce O'shaughnessy, Md, MD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Dr. Thomas Hutson, Do,Pharmd, DO,PHARMD
Medical Oncology — Payments: $1.3M
Medical Oncology $1.3M
Dr. Tian Zhang, M.d, M.D
Medical Oncology — Payments: $395,066
Medical Oncology $395,066
Dr. Stephen Jones, Md, MD
Medical Oncology — Payments: $221,960
Medical Oncology $221,960